News

There are currently no FDA-approved therapies for the rare, genetic disease.

Experts Heather Woolery-Lloyd, MD; Chesahna Kindred, MD, MBA, FAAD; Gary M. Owens, MD; and Renata Block, MMS, PA-C, discuss the evolving landscape of vitiligo, particularly from an economic lens.

The partnership will combine dermatological expertise and Absci's Integrated Drug Creation platform.

This week’s collection of the latest dermatologic studies covers atypical molluscum contagiosum lesions with a CD30-positive T-cell lymphoid infiltrate, comorbidities in pediatric psoriasis, tralokinumab for adolescents with severe AD, and intralesional bleomycin combined with lidocaine for recalcitrant keloid scars.

Dermatology Times, the SDPA, and more are celebrating the invaluable contributions of nurse practitioners in dermatology this NP Week (November 12-18).

Label warnings may affect the initiation of new treatment and real-world switching patterns for psoriasis patients starting treatment with risankizumab.

Experts discuss insights and hot topics stemming from this year's Science of Skincare Summit, including upcoming innovations and considerations in dermatology.

In honor of National Healthy Skin Month, it is the perfect time to encourage patients to integrate gentle laser treatments into their yearly routine to maintain healthy, radiant skin.

Bimekizumab is the first dual IL-17 A/F inhibitor to treat moderate-to-severe plaque psoriasis. It launches with a list price of $7,200 per syringe.

In addition to improvements in work productivity, tildrakizumab also demonstrated significant efficacy and safety.

Dermatology encompasses cosmetics, unregulated products, OTC drugs, OTC devices, prescription devices, and prescription drugs, whether oral, injectable, or topical.

2023 has been complete with numerous innovations in the dermatology space, including in atopic dermatitis, psoriasis, alopecia areata, and more.

In this week’s Pointers With Portela, the 208SkinDoc reviews medical health insurance on his podcast.

Keep up with the latest headlines in dermatology from the past week, including the rise of teledermatology platforms leading patients to opt out of in-person consultations, WHO and ILO estimates of non-melanoma skin cancer deaths attributable to outdoor work in the sun, and more.

ICYMI, this week we had articles about a proposed ban of formaldehyde in hair relaxers, TAK-279 for psoriatic arthritis, and updated atopic dermatitis guidelines from AAD.

Shawn Kwatra, MD, shares his thoughts on the positive phase 3 data of OLYMPIA 2.

Catch up on the best highlights from Maui Derm NP + PA Fall, Inflammatory Disease Summit, and SDPA Fall.

Grants allow investigators to uncover the potential causes and key aspects of rosacea to pave the way for improved treatment, prevention, and possibly a cure.

Susan C. Taylor, MD, FAAD, and George Han, MD, PhD, share insights on vitiligo awareness, demographics, treatment approaches, and the impact of the condition on patients’ quality of life.

Investigators noted that patients with mild psoriasis experience a less favorable status when compared to patients with moderate psoriasis.

Data from Novartis will be presented at the 2023 American College of Allergy, Asthma, and Immunology Scientific Meeting.

Click here to answer this week's poll for hyperhidrosis awareness month.

The case of a 45-year-old woman with AD challenges clinicians on how to consider stress as an exacerbating factor in a treatment-resistant case.

Catch up on the best highlights from Fall Clinical for PAs & NPs, SDPA Summer, and Maui Derm NP + PA Summer.

The guidelines update AAD’s 2014 recommendations for the management of AD with phototherapy and systemic therapies.

Kwatra discussed his research team’s findings published in JAMA Dermatology.

New lifestyle transitions can affect a patient's treatment adherence and support network. How would you help this new college student?

In this week’s Pointers With Portela, the 208SkinDoc discusses the best retinol alternatives in 2023.

Despite how widely used these acids often are, there is still a lack of general consensus for which are the most effective in patients with acne-prone skin.

Vilobelimab has received Fast Track and Orphan Drug designations from the FDA, as well as an Orphan Drug designation from the European Medicines Agency for the treatment of PG.